Treating rare breast cancer with radiation therapy may lower recurrence rate

Jul 11, 2008

Patients with a rare type of breast cancer may benefit from receiving radiation therapy in addition to surgery to prevent recurrence, according to a study in the July issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

Phyllodes tumors are rare breast tumors that develop in the connective tissue of the breast, as opposed to more common carcinomas, which develop in the ducts or lobules of the breast. Most patients are treated for phyllodes tumors with either a lumpectomy or mastectomy, with only a small fraction of patients receiving radiation therapy.

Traditionally, adjuvant radiation therapy is recommended for cancer patients with local recurrence risks of 15 percent or greater, but the value of adjuvant radiation therapy has not been extensively studied for phyllodes tumors because they are so rare.

Researchers at the Division of Radiation Oncology, Department of Medical Physics, and Department of General and Oncologic Surgery at City of Hope National Medical Center in Duarte, Calif., sought to determine the local recurrence rates of phyllodes tumors based on tumor size and the type of surgery performed and whether adjuvant radiation therapy should be considered as a treatment for some phyllodes tumor patients to reduce their local recurrence rate.

"Typically these tumors are treated well by surgery alone. However, local recurrences are not uncommon," Richard Pezner, M.D., lead author of the study and a radiation oncologist at City of Hope National Medical Center in Duarte, Calif., said.

The study authors reviewed records of 478 patients with malignant phyllodes tumors who were treated between March 1964 and August 2005. The records came from the IMPAC National Oncology Database, which consists of tumor registries from 130 hospitals.

The researchers found that the risk of local recurrence for phyllodes tumors was related to tumor size and the type of surgery received. They determined that adjuvant radiation therapy should be evaluated for phyllodes tumor patients who received lumpectomies for tumors at least 2 centimeters in size or a mastectomy for tumors at least 10 centimeters in size to reduce the risk of recurrence.

Source: American Society for Therapeutic Radiology and Oncology

Explore further: Cancer waiting time targets – simply not good enough

Related Stories

Graphene and diamonds prove a slippery combination

30 minutes ago

Scientists at the U.S. Department of Energy's Argonne National Laboratory have found a way to use tiny diamonds and graphene to give friction the slip, creating a new material combination that demonstrates ...

Study links credit default swaps, mortgage delinquencies

40 minutes ago

Researchers at The University of Texas at Dallas recently published the first empirical investigation connecting credit default swaps to mortgage defaults that helped lead to the 2007-2008 financial crisis.

NASA image: Hubble revisits tangled NGC 6240

10 minutes ago

Not all galaxies are neatly shaped, as this new NASA/ESA Hubble Space Telescope image of NGC 6240 clearly demonstrates. Hubble previously released an image of this galaxy back in 2008, but the knotted region, shown ...

Recommended for you

Vortex device makes for better cancer treatments

May 22, 2015

A South Australian invention, responsible for unboiling an egg, has been used to produce a four-fold increase in efficacy of carboplatin, a commonly used drug for ovarian, lung and other cancer. ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
not rated yet Jul 12, 2008
X-ray is one of the best ways to disrupt the orderly operation of a cell and produce cancer!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.